Final Results - Part 3 of 3

AstraZeneca PLC 27 January 2005 AstraZeneca Development Pipeline: NCEs and line extensions 27 January 2005 Cardiovascular NCEs Compound Mechanism Area under investigation Phase Estimated Filing MAA NDA Exanta thrombin inhibitor prevention of VTE III Launched Filed* Exanta thrombin inhibitor (s.c.) prevention of VTE III Launched >2007 SC formulation Galida PPAR agonist diabetes /metabolic III 2007 2007 syndrome AZD6140 ADP receptor antagonist arterial thrombosis II >2007 >2007 AZD7009 antiarrhythmic IV atrial fibrillation - II >2007 >2007 conversion AZD7009 antiarrhythmic oral atrial fibrillation - II >2007 >2007 maintenance AZD9684 CPU inhibitor thrombosis II >2007 >2007 AZD0837 thrombin inhibitor thrombosis II >2007 >2007 AZD7806 IBAT inhibitor dyslipidaemia I >2007 >2007 AZD4619 dyslipidaemia I >2007 >2007 AZD6610 dyslipidaemia/diabetes I >2007 >2007 AZD8294 dyslipidaemia PC >2007 >2007 AZD8677 dyslipidaemia/diabetes PC >2007 >2007 AZD8450 dyslipidaemia PC >2007 >2007 AZD6370 diabetes PC >2007 >2007 Line Extensions Atacand angiotensin II antagonist CHF outcomes III Approved Filed (CHARM study) Atacand angiotensin II antagonist diabetic retinopathy III > 2007 >2007 Crestor statin atheroma III 2H2006 2H2006 Crestor statin outcomes CHF III >2007 >2007 Crestor statin outcomes Renal III 2007 2007 Seloken/Toprol-XL beta-blocker HCTZ combination III 3Q2005 Exanta thrombin inhibitor prevention of stroke in III Filed Filed* AF Exanta thrombin inhibitor treatment of VTE III Filed >2007 Exanta thrombin inhibitor arterial/post MI II >2007 >2007 * Discussions are ongoing with the FDA to determine if there is now a realistic prospect of bringing Exanta to the US market. The NDA file remains open. Gastrointestinal NCEs Compound Mechanism Area under Phase Estimated Filing investigation MAA NDA AZD0865 potassium-competitive acid acid related GI disease II 2007 2007 blocker (P-CAB). AZD7371 functional GI disease II >2007 >2007 AZD3355 inhibitor of transient lower gastro-oesophageal I >2007 >2007 oesophageal sphincter reflux disease (GERD) relaxations (TLESR) AZD9343 inhibitor of transient lower gastro-oesophageal I >2007 >2007 oesophageal sphincter reflux disease (GERD) relaxations (TLESR) AZD5745 acid related GI disease PC >2007 >2007 AZD8081 functional GI disease PC >2007 >2007 Line Extensions Nexium proton pump inhibitor NSAID GI side effects - III Promotable* Filed symptom resolution Nexium proton pump inhibitor parenteral formulation III Launched Filed Nexium proton pump inhibitor NSAID GI side effects - III Launched Launched ulcer prevention Nexium proton pump inhibitor NSAID GI side effects - III Launched Filed ulcer healing Nexium proton pump inhibitor extra-oesophageal II >2007 >2007 reflux disease * Authorities stated these symptoms were already captured within the GERD label. Text stating 'No clinical interaction with naproxen or rofecoxib' was approved. Neuroscience NCEs Compound Mechanism Area under Phase Estimated Filing investigation MAA NDA Cerovive free radical trapping agent stroke III 2H 2006 2H 2006 AZD 7371 overactive bladder II >2007 >2007 AZD8129 (AR-A2) 5HT1B antagonist anxiety/depression II >2007 >2007 AZD4282 NMDA antagonist neuropathic pain I >2007 >2007 AZD3102 Alzheimer's disease PC >2007 >2007 AZD1080 Alzheimer's disease PC >2007 >2007 AZD9272 neuropathic pain PC >2007 >2007 AZD2327 anxiety PC >2007 >2007 AZD5904 multiple sclerosis PC >2007 >2007 AZD6538 neuropathic pain PC >2007 >2007 Line Extensions Seroquel D2/5HT2 antagonist sustained release III 1H 2006 1H 2006 Seroquel D2/5HT2 antagonist bipolar maintenance III 2007 2007 Seroquel D2/5HT2 antagonist bipolar depression III 2007 1H 2006 Oncology and Infection NCEs Compound Mechanism Area under Phase Estimated Filing investigation MAA NDA Iressa EGFR-TK inhibitor NSCLC III Withdrawn Launched ZD6474 angiogenesis inhibitor solid tumours II >2007 >2007 (VEGFR-TKI) ZD4054 endothelin A receptor solid tumours II >2007 >2007 antagonist AZD2171 angiogenesis inhibitor solid tumours I >2007 >2007 (VEGFR-TKI) AZD3409 farnesyl-transferase solid tumours I >2007 >2007 inhibitor ( FAR ) AZD0530 SRC kinase inhibitor solid tumours and I >2007 >2007 haematological malignancies AZD5438 selective cyclin dependent solid tumours I >2007 >2007 kinase inhibitor AZD6244 MEK inhibitor solid tumours I >2007 >2007 ZD6126 vascular targeting agent solid tumours PC >2007 >2007 AZD4440 vascular targeting agent solid tumours PC >2007 >2007 AZD9935 angiogenesis inhibitor solid tumours PC >2007 >2007 (VEGFR-TKI) AZD0424 SRC kinase inhibitor solid tumours PC >2007 >2007 AZD1152 aurora kinase inhibitor solid tumours and PC >2007 >2007 haematological malignancies AZD4769 solid tumours PC >2007 >2007 AZD3841 solid tumours PC >2007 >2007 AZD8931 solid tumours PC >2007 >2007 Line Extensions Merrem carbapenem antibiotic skin and soft tissue III Filed infections Faslodex oestrogen receptor 1st line advanced III >2007 >2007 antagonist breast cancer Iressa EGFR-TK inhibitor head & neck cancer* III 2H 2006 2H 2006 Iressa EGFR-TK inhibitor breast cancer* II >2007 >2007 Iressa EGFR-TK inhibitor colorectal cancer* II >2007 >2007 * under review Respiratory and Inflammation NCEs Compound Mechanism Area under Phase Estimated Filing investigation MAA NDA AZD9056 ion channel blocker rheumatoid arthritis II >2007 >2007 AZD9056 ion channel blocker osteoarthritis II >2007 >2007 AZD8309 chemokine receptor antagonist rheumatoid arthritis I >2007 >2007 AZD8955 collagenase inhibitor osteoarthritis I >2007 >2007 AZD8309 chemokine receptor antagonist COPD I >2007 >2007 AZD3778 chemokine receptor antagonist asthma / rhinitis I >2007 >2007 AZD9056 ion channel blocker COPD I >2007 >2007 AZD3342 protease inhibitor COPD I >2007 >2007 AZD6067 protease inhibitor COPD PC >2007 >2007 AZD2098 asthma PC >2007 >2007 AZD1981 asthma PC >2007 >2007 AZD0902 ion channel blocker rheumatoid arthritis PC >2007 >2007 AZD6703 rheumatoid arthritis PC >2007 >2007 AZD6357 osteoarthritis PC >2007 >2007 AZD7928 COPD PC >2007 >2007 AZD2914 COPD PC >2007 >2007 AZD2392 asthma/rhinitis PC >2007 >2007 AZD1744 asthma/rhinitis PC >2007 >2007 AZD5672 rheumatoid arthritis PC >2007 >2007 Line Extensions Symbicort Turbuhaler inhaled steroid/fast onset, single therapy for III 2H 2005 long-acting ss2 agonist asthma Symbicort pMDI inhaled steroid/fast onset, asthma III Filed 2Q/3Q 2005* long-acting ss2 agonist Symbicort pMDI inhaled steroid/fast onset, COPD III Filed 2007 long-acting ss2 agonist * US development of the Symbicort pMDI is progressing and the Phase III clinical programme in asthma is complete. Following a pre-NDA meeting with the FDA in the fourth quarter of 2004, an NDA filing for this formulation is now targeted for Q2/Q3 2005, although FDA has identified some issues associated with the inhaler that require the generation of additional chemistry and manufacturing data or possible modification of the device in order to achieve approval. AstraZeneca Development Pipeline: Discontinued Projects 6 October 2004 vs. 27 January 2005 Cardiovascular NCE /Line Extension Compound Area under investigation NCE AZD0303 thrombosis Gastrointestinal NCE /Line Extension Compound Area under investigation NCE AZD9139 Acid related GI disease Comments As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time. Compounds in development are displayed by phase. Abbreviations: PC - Pre-clinical: Candidate Drug accepted for development but not yet administered to man. MAA - Marketing Authorisation Application (Europe) NDA - New Drug Application (USA) NCE - New Chemical Entity This information is provided by RNS The company news service from the London Stock Exchange

Companies

AstraZeneca (AZN)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today